Treatment of hepatitis c virus infection in liver transplant recipients

Gastroenterology and Hepatology

Volumn 12, Issue 1, 2016, Pages 23-30

  Suraweera, Duminda ^a   Sundaram, Vinay ^b   Saab, Sammy ^c  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

Direct Acting Antiviral Agents; Hepatitis C Virus; Liver Transplant; Recurrence; Viral Hepatitis

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR; ELBASVIR; GRAZOPREVIR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR;

ANTIVIRAL THERAPY; ARTICLE; COMPASSIONATE USE; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT REFUSAL; VIRAL CLEARANCE;

EID: 84957684028     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Kim WR, Stock PG, Smith JM, et al. OPTN/SRTR 2011 Annual Data Report: liver. Am J Transplant. 2013;13(suppl 1):73-102.
2. Busuttil RW, Farmer DG, Yersiz H, et al. Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg. 2005;241(6):905-916.
3. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122(4):889-896.
4. Pelletier SJ, Schaubel DE, Punch JD, Wolfe RA, Port FK, Merion RM. Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl. 2005;11(4):434-440.
5. Roche B, Sebagh M, Canfora ML, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008;14(12):1766-1777.
6. Stepanova M, Wai H, Saab S, Mishra A, Venkatesan C, Younossi ZM. The portrait of an adult liver transplant recipient in the United States from 1987 to 2013. JAMA Intern Med. 2014;174(8):1407-1409.
7. Thuluvath PJ, Krok KL, Segev DL, Yoo HY. Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl. 2007;13(5):719-724.
8. Biggins SW, Bambha KM, Terrault NA, et al. Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl. 2012;18(12):1471-1478.
9. Saab S, Rheem J, Sundaram V. Hepatitis C infection in the elderly. Dig Dis Sci. 2015;60(11):3170-3180.
10. Kawaoka T, Takahashi S, Kawakami Y, et al. Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation. Hepatol Res. 2014.
11. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation. 2004;77(2):190-194.
12. Lavezzo B, Franchello A, Smedile A, et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol. 2002;37(2):247-252.
13. Narayanan Menon KV, Poterucha JJ, El-Amin OM, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl. 2002;8(7):623-629.
14. Shakil AO, McGuire B, Crippin J, et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology. 2002;36(5):1253-1258.
15. Bizollon T, Palazzo U, Ducerf C, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology. 1997;26(2):500-504.
16. Samuel D, Bizollon T, Feray C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology. 2003;124(3):642-650.
17. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015; 385(9973):1124-1135.
18. Saab S, Manne V, Bau S, et al. Boceprevir in liver transplant recipients. Liver Int. 2015;35(1):192-197.
19. Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014;60(1):78-86.
20. Ikegami T, Yoshizumi T, Yoshida Y, et al. Telaprevir versus simeprevir for the treatment of recurrent hepatitis C after living donor liver transplantation [published online June 19, 2015]. Hepatol Res. doi:10.1111/hepr.12546.
21. Werner CR, Franz C, Egetemeyr DP, et al. Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment. J Viral Hepat. 2014;21(5):333-340.
22. Nair S, Waters B. Telaprevir in treatment of recurrent hepatitis C infection in liver transplant recipients. Exp Clin Transplant. 2014;12(2):117-122.
23. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148(1):108-117.
24. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61(5):1485-1494.
25. Brown RS, Reddy KR, O'Leary JG, et al. Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study [AASLD abstract LB-4]. Hepatology. 2014;60(5 suppl).
26. Charlton M, Everson GT, Flamm SL, et al; SOLAR-1 Investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649-659.
27. Saab S, Greenberg A, Li E, et al. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver Int. 2015;35(11): 2442-2447.
28. Pungpapong S, Aqel B, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015;61(6):1880-1886.
29. Gutierrez JA, Carrion AF, Avalos D, et al. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl. 2015;21(6):823-830.
30. Coilly A, Fougerou C, De Ledinghen V, et al. The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation. Presented at the Annual Meeting of the European Association for the Study of the Liver; Vienna, Austria; April 22-26, 2015. Abstract G15.
31. Leroy V, Dumortier J, Coilly A, et al. Major clinical improvement during sofosbuvir and daclatasvir-based regimens for the treatment of fibrosing cholestatic HCV-recurrence after liver transplantation: the ANRS CO23 CUPILT study. Presented at the American Association for the Study of Liver Diseases Liver Meeting; Boston, Massachusetts; November 7-12, 2014. Abstract 21.
32. Pellicelli AM, Montalbano M, Lionetti R, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis. 2014;46(10):923-927.
33. Poordad F, Schiff E, Vierling J, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study. [EASL abstract LO8]. J Hepatol. 2015;62(1 suppl).
34. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371(25):2375-2382.
35. Jacobson IM, Poordad F, Firpi-Morell R, et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child-Pugh class B cirrhosis (C-SALT Part A) [EASL abstract O008]. J Hepatol. 2015;62(1 suppl).
36. Kwo PY, Gane E, Peng CY, et al. Grazoprevir/elbasvir shows excellent activity in prior non-responders to interferon-based therapies. Presented at Digestive Disease Week; Washington, DC; May 16-19, 2015. Abstract 901f.
37. Saab S, Jimenez M, Bau S, et al. Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis. Clin Transplant. 2015;29(9):813-819.
38. Campos-Varela I, Peters MG, Terrault NA. Advances in therapy for HIV/ hepatitis C virus-coinfected patients in the liver transplant setting. Clin Infect Dis. 2015;60(1):108-116.
39. Foster GR, McLauchlan J, Irving W, et al. Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3 [EASL abstract O002]. J Hepatol. 2015;62(1 suppl).
40. Dvory-Sobol H, Wyles D, Ouyang W, et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir [abstract O059]. J Hepatol. 2015;60(suppl 2).
41. Krishnan P, Tripathi R, Schnell G, et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir-and dasabuvir-based regimens [abstract O057]. J Hepatol. 2015;60(suppl 2).
42. Lawitz E, Flamm S, Yang YV, et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks [abstract O005]. J Hepatol. 2015;60(suppl 2).
43. Hep-Drug Interactions. The University of Liverpool. http://www.hep-druginteractions.org. Accessed August 14, 2015.